# A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults

> **NCT02420444** · PHASE1 · COMPLETED · sponsor: **Aeras** · enrollment: 70 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** BCG SSI
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AERAS-404

## Key facts

- **NCT ID:** NCT02420444
- **Lead sponsor:** Aeras
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-05
- **Final completion:** 2013-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420444, "A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02420444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*